Andrea (Andy) Coravos
CEO and Co-founder @ HumanFirst
Boston, United States
Andrea (Andy) Coravos is a seed investor at HumanFirst in Boston focused on Health Care and Artificial Intelligence. Andrea (Andy) Coravos - CEO and Co-founder @ HumanFirst
- Total investments:
- 16
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Andrea (Andy) Coravos invests in
Stages Andrea (Andy) Coravos invests in
Countries Andrea (Andy) Coravos invests in
Round sizes
Round size
- Seed
- $1M–$11M
- Series A
- $10M–$20M
- Series B
- $25M–$110M
Investment Focus
Industry
- Health Care 7 (44%)
- Artificial Intelligence 6 (38%)
- Biotechnology 5 (31%)
- Software 4 (25%)
- Personal Health 4 (25%)
Stage
- Seed 7 (44%)
- Series B 4 (25%)
- Series A 2 (13%)
- Pre-Seed 1 (6%)
- Series C 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Blue
|
Blue is an AI-powered EHR purpose-built for healthspan/longevity practices that gives doctors superhuman abilities, synced seamlessly with a personal health superapp for me and you.Imagine a healthcare system that actually takes care of your health *in advance* rather than fumbling to pick up the pieces after things go wrong.We'repassionate about a future in which far more diseases are prevented than treated, and it's effortless to improve your day-to-day quality of life, in both well-being and performance.Science >> Snake Oil | Pre-Seed / Jul 04, 2024 | |
Loyal
|
Loyal is a veterinary biotechnology company that develops pharmaceutical therapies for dogs aimed at extending their healthy lifespan and delaying age-associated diseases. It researches and formulates drug candidates designed to address the biological mechanisms of aging in different dog populations, including senior and large-breed dogs, withproducts progressing through clinical and regulatory pathways. Loyal engages in clinical studies and collaborates with veterinary professionals to advance its therapeutic programs and share scientific insights with the broader field. The company publishes research summaries to support transparency and enable other practitioners to build on its findings. | $45M / Series B / Mar 21, 2024 | |
Morf Health
|
Morf Health is making it 10x faster for healthcare providers to setup and maintain integrations across their tech stack, e.g. easily structure data from patient intake and send to an EHR. We pull data out of the tools they use to deliver care and run the business, unify and normalize the data, and then send it to the tools that need it. | $3M / Seed / Nov 14, 2023 | |
Legacy
|
Legacy provides a service for at-home sperm testing and cryopreservation, allowing individuals to take control of their fertility health from the comfort of their homes. Their semen analysis is conducted in CLIA-certified labs, ensuring high-quality testing without the need for direct doctor involvement. As America's largest at-home fertilityclinic for men, Legacy empowers clients to understand their reproductive health and plan for the future effectively. | $25M / Series B / May 12, 2023 | |
Infinity AI
|
Infinity AI is a technology startup that builds AI models faster with synthetic data. The startup's parameterized generators provide complete control over synthetic data distributions such as body shape, skin tone, lighting conditions, camera angles, and other factors. Its engineers can upload a single real-world video and turn it intohundreds of identical and perfectly labeled synthetic videos using the platform. Infinity uses a combination of physics-based simulations and generative techniques to do this.The company is based in San Francisco, California. | $5M / Seed / Dec 15, 2022 | |
Rootine
|
Rootine is optimizing health and human performance with precision nutrition. We're combining science and technology to change the game in personalized nutrition. Leveraging best-in-class AI, and considering individual DNA, blood, and lifestyle test results not only to create the most accurate nutrient formula for your body, but deliver itthrough precision dosing, and enable you to track your health progress overtime. | $10M / Series A / Sep 13, 2022 | |
Orchid
|
Orchid is a reproductive technology startup that is capable of detecting rare genetic disorders. Orchid’s preconception system analyzes both partners’ genomes and assesses genetic predispositions to common diseases, including heart disease, stroke, schizophrenia, Alzheimer’s disease, breast cancer, and diabetes. Orchid results are developed withworld-class experts in reproductive medicine and genetics to give its clients the most accurate results.Orchid offers a “Couple Report” that utilizes an at-home saliva test to analyze each person’s genomes to detect the probability of genetic risks, then models how their DNA together will combine in a future child. If elevated risk is detected, Orchid provides insights to help couples monitor biomarkers, adapt their diet or elect for procedures, such as in vitro fertilization. It was founded by Noor Siddiqui in 2019 and is headquartered in San Francisco, California. | Seed / Aug 31, 2022 | |
Freedom Biosciences
|
Freedom Biosciences is a biotechnology platform developing next-generation psychedelic therapeutics. | $10.5M / Seed / Aug 23, 2022 | |
Vibe Bio
|
Vibe Bio is a community of patients, scientists, and partners committed to identifying, funding, and developing promising treatments for rare diseases and empowering patient communities with unprecedented ownership over the process. | $12M / Venture - Series Unknown / Jun 22, 2022 | |
Vanta
|
Vanta provides an AI-powered Trust Management Platform that automates compliance, security, and risk management for businesses. It helps companies achieve and maintain compliance with various frameworks, streamlining the audit process. The platform also offers solutions for vendor risk management and questionnaire automation, helping businessesbuild and prove trust continuously. | $110M / Series B / Jun 08, 2022 | |
| See all 16 investments → | |||
Co-Investors
About HumanFirst
HumanFirst accelerates the adoption of patient-centered clinical trials using precision digital measures (e.g., digital biomarkers and eCOA).At HumanFirst, we offer a precision measures platform - the world’s largest AI-powered SaaS platform trusted to improve human outcomes. We provide insights, intelligence, and accuracy with validated evidencedata to precisely guide and accelerate human-centric drug development. Twenty-two of the 25 largest pharmaceutical companies in the world have used the HumanFirst platform to evaluate and enable the deployment of digital health technologies (DHTs).
HumanFirst Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Andrea (Andy) Coravos
CEO and Co-founder
|
|||
Christine Manta
Head of Customer Experience and Operations Lead
|
|||
Dena Mendelsohn
Director, Health Policy and Data Governance
|
|||
Sofia Warner
Co-Founder and Advisor
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Andrea (Andy) Coravos invest in?
Andrea (Andy) Coravos invests primarily in Health Care, Artificial Intelligence and Biotechnology startups, most often at Seed and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Andrea (Andy) Coravos's check size?
Andrea (Andy) Coravos typically joins rounds of $1M–$11M at Seed, $10M–$20M at Series A and $25M–$110M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Andrea (Andy) Coravos participates in.
When did Andrea (Andy) Coravos last invest?
The most recent investment recorded for Andrea (Andy) Coravos closed in Jul 2024. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
